Earnings Call · Q2 FY2024·2024-08-06

Q2 24EPS -6.25%·Rev n/aQ1 24EPS -4.17%·Rev n/aQ4 23EPS -30.77%·Rev n/aQ3 23EPS -13.79%·Rev n/a⚠ consensus missing

SANGAMO THERAPEUTICS, INC SGMO

Louise Wilkie — Vice President of Investor Relations and Corporate Communications

Sandy Macrae — Chief Executive Officer

Nathalie Dubois-Stringfellow — Chief Development Officer

−13.5%1d on move date−12.8% vs SPY3d+3.0%5d−1.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SGMO calls or request research access.

More SGMO calls Browse calls Request research access